Major Milestone: FDA Approves Novel Drug Developed By This Company

ImmunityBio's BLA Resubmission Accepted by FDA: A New PDUFA Date Set and What it Means for You

Introduction

In the ever-evolving landscape of biotechnology, understanding the implications of regulatory milestones is essential. The U.S. Food and Drug Administration (FDA) recently accepted ImmunityBio Inc.'s (NASDAQ: IBRX) Biologics License Application (BLA) resubmission, setting a new Prescription Drug User Fee Act (PDUFA) date. This article will d…